Cytokinetics Q2 net loss narrows to $134.4M; aficamten PDUFA set Dec 26, 2025

CYTOKINETICS INC

2025-Q2 EPS reported -$2.49 revenue$68,348,000

Net loss of $134.4M ($1.12/sh) vs $143.3M ($1.31/sh) in Q2 2024; revenue $66.8M from Bayer deal.
Cash, cash equivalents and investments: $1.0B at June 30, down $52.6M QoQ after $75M loan draw.
FDA late-cycle meeting for aficamten (obstructive HCM) scheduled Sept 2025; PDUFA Dec 26, 2025.
MAPLE-HCM primary results to be presented in Hot Line Session at ESC 2025.
FY 2025 GAAP operating expense guidance maintained at $670M-$710M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.